Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2024.115192 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Natalie Dennis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi Sankyo Oncology France, Rueil-Malmaison, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Ado-Trastuzumab Emtansine, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi-Sankyo, AstraZeneca, Daiichi Sankyo Europe GmbH.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Daiichi Sankyo Oncology France, Rueil-Malmaison, France.
- Daiichi Sankyo, London, United Kingdom.
- AstraZeneca, London, United Kingdom.
- Putnam, Ceva House, Excelsior Road, Ashby-De-La-Zouch LE65 1NG, United Kingdom. Electronic address: nataliya.bogoeva@putassoc.com.
- Putnam, Ceva House, Excelsior Road, Ashby-De-La-Zouch LE65 1NG, United Kingdom.
- Sarah Cannon Research Institute, Nashville, United States.
Förderung
- Daiichi-Sankyo
- AstraZeneca
- Daiichi Sankyo Europe GmbH
Zitieren
APA
Dennis, N., Dunton, K., Livings, C., Bogoeva, N., Bourke, S., Oluboyede, Y., Hamilton, E., Iwata, H., & Cortés, J. (2025). Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115192
Vancouver
Dennis N, Dunton K, Livings C, Bogoeva N, Bourke S, Oluboyede Y, et al. Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2024.115192
BibTeX
@article{Dennis2025,
author = {Dennis, Natalie and Dunton, Kyle and Livings, Christopher and Bogoeva, Nataliya and Bourke, Siobhan and Oluboyede, Yemi and Hamilton, Erika and Iwata, Hiroji and Cortés, Javier},
title = {Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2024.115192}
}
EUVIMED